Bibliographic Details
| Title: |
INSIG2polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine |
| Authors: |
Koskinen, Suvi, Kampman, Olli, Solismaa, Anssi, Lyytikäinen, Leo-Pekka, Seppälä, Niko, Viikki, Merja, Hämäläinen, Mari, Moilanen, Eeva, Mononen, Nina, Lehtimäki, Terho, Leinonen, Esa |
| Source: |
Pharmacogenomics; December 2016, Vol. 17 Issue: 18 p1987-1997, 11p |
| Abstract: |
Aim:To investigate INSIG2'sassociation with obesity, weight change and serum lipid profile during clozapine treatment. Materials & methods:Subjects with schizophrenia (n 190) were genotyped, identifying seven SNPs. Genetic risk scores (GRSs) were calculated to adiponectin, high-density lipoprotein cholesterol, triglycerides and weight gain. Results:In the model for weight gain, SNPs rs12151787, rs17047733 and rs10490626 were selected. Explanatory variables were BMI (p 5.05 × 10-5), age (p 0.003) and GRS (p 2.81 × 10-5, p 0.0002 after permutation). No GRS resulted for adiponectin or high-density lipoprotein cholesterol. Rs2161829 and rs10490620 were selected for triglycerides; this GRS was insignificant after permutation. Conclusion:INSIG2plays a role in weight gain and obesity during clozapine treatment. |
| Database: |
Supplemental Index |
